Literature DB >> 12717048

Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men.

Frank Romanelli1, Kelly M Smith, Claire Pomeroy.   

Abstract

Club drugs such as methylenedioxymethamphetamine (MDMA, ecstasy), gamma hydroxybutyrate (GHB), and ketamine are among the fastest-growing drugs of abuse in the United States. Reports have shown that some gay and bisexual men are likely to engage in club-drug use in a myriad of venues. This is concerning given that the use of club drugs has been linked to high-risk sexual behaviors. Further, the use of club drugs by HIV-seropositive individuals may have detrimental outcomes on disease progression by either influencing adherence, resulting in drug-drug interactions with antiretrovirals, or potentially compounding immune suppression. Clinicians caring for HIV-seropositive and -seronegative individuals should be aware of the clinical effects and management guidelines associated with these chemicals. This article reviews the available literature with regard to the use of club drugs by HIV-seropositive and -seronegative gay and bisexual men. Although club-drug use may be associated with many risk behaviors for HIV infection, this review focuses on risk behavior among gay and bisexual men since this is the group for which the most data have been reported. The clinical effects and management guidelines associated with these agents are described, and the potential detrimental effects of these substances on HIV disease are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717048

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  21 in total

1.  Consistency and change in club drug use by sexual minority men in New York City, 2002 to 2007.

Authors:  David W Pantalone; David S Bimbi; Catherine A Holder; Sarit A Golub; Jeffrey T Parsons
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

2.  Adolescent sexual orientation.

Authors: 
Journal:  Paediatr Child Health       Date:  2008-09       Impact factor: 2.253

3.  Ecstasy use and its association with sexual behaviors among drug users in New York City.

Authors:  Roberto A Novoa; Danielle C Ompad; Yingfeng Wu; David Vlahov; Sandro Galea
Journal:  J Community Health       Date:  2005-10

4.  Predictors of day-level sexual risk for young gay and bisexual men.

Authors:  Jeffrey T Parsons; Corina Lelutiu-Weinberger; Michael Botsko; Sarit A Golub
Journal:  AIDS Behav       Date:  2013-05

5.  Methamphetamine-using HIV-positive men who have sex with men: correlates of polydrug use.

Authors:  Thomas L Patterson; Shirley J Semple; James K Zians; Steffanie A Strathdee
Journal:  J Urban Health       Date:  2005-02-28       Impact factor: 3.671

6.  Poly-club-drug use among gay and bisexual men: a longitudinal analysis.

Authors:  Perry N Halkitis; Joseph J Palamar; Preetika Pandey Mukherjee
Journal:  Drug Alcohol Depend       Date:  2007-01-30       Impact factor: 4.492

7.  Circumstances of initiation into new-type drug use among adults in Shanghai: are there differences by types of first new-type drug used?

Authors:  Yingying Ding; Na He; Roger Detels
Journal:  Drug Alcohol Depend       Date:  2013-01-09       Impact factor: 4.492

8.  A randomized controlled trial utilizing motivational interviewing to reduce HIV risk and drug use in young gay and bisexual men.

Authors:  Jeffrey T Parsons; Corina Lelutiu-Weinberger; Michael Botsko; Sarit A Golub
Journal:  J Consult Clin Psychol       Date:  2013-12-23

9.  Prevalence of non-medical drug use and dependence among homosexually active men and women in the US population.

Authors:  Susan D Cochran; Deborah Ackerman; Vickie M Mays; Michael W Ross
Journal:  Addiction       Date:  2004-08       Impact factor: 6.526

10.  Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths.

Authors:  Li-Tzy Wu; William E Schlenger; Deborah M Galvin
Journal:  Drug Alcohol Depend       Date:  2006-02-17       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.